The biosimilar Hyrimoz showed similar flare rates to Humira, but 25% of patients experienced adverse events, mainly injection site reactions. Injection pain, linked to Hyrimoz's citrate content and ...

Patients with uveitis exhibited lower risk for TB with adalimumab therapy, though the risk was not completely eliminated.

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Patients in early rheumatoid arthritis respond well to either abatacept or adalimumab, with the ...

Humira (adalimumab) is a long-term maintenance medication used to manage chronic conditions like Crohn’s disease and rheumatoid arthritis. For many people, this drug is not a short-term fix but a ...

Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis and higher rheumatoid factor demonstrated better DAS28-CRP improvement with ...

Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the treatment ...

Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy while on prednisone were more likely to have their corticosteroid dose reduced or systemic ...

Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients with hidradenitis suppurativa, post hoc analysis of the PIONEER I and II ...

Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...

Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...

Adalimumab significantly reduces activity limitations and boosts work ability and quality of life in patients with psoriasis. Following patients with psoriasis for up to 5 years after initiating ...